Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, has announced plans to advance its investigational drugs SION-719 and SION-451 to the next stage of clinical development. SION-719 will be evaluated in a Phase 2a proof-of-concept trial as an add-on to the standard of care in cystic fibrosis patients. Additionally, SION-451 will undergo a Phase 1 trial in healthy volunteers, testing dual combinations with SION-2222 and SION-109. Both trials are set to commence in the second half of 2025, with data expected by mid-2026. Preclinical data demonstrating the potential of these dual combinations to achieve full CFTR correction in CF models were presented at the 48th European Cystic Fibrosis Conference.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。